Kesler Norman & Wride LLC Acquires Shares of 443 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Kesler Norman & Wride LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 443 shares of the biopharmaceutical company’s stock, valued at approximately $316,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Groupama Asset Managment raised its position in Regeneron Pharmaceuticals by 12.7% in the fourth quarter. Groupama Asset Managment now owns 80,339 shares of the biopharmaceutical company’s stock worth $56,445,000 after acquiring an additional 9,062 shares during the period. Trexquant Investment LP increased its stake in shares of Regeneron Pharmaceuticals by 305.9% during the 4th quarter. Trexquant Investment LP now owns 56,625 shares of the biopharmaceutical company’s stock worth $40,336,000 after purchasing an additional 42,674 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock worth $1,726,940,000 after purchasing an additional 155,369 shares during the period. Franklin Resources Inc. lifted its stake in Regeneron Pharmaceuticals by 7.9% in the fourth quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company’s stock valued at $1,456,864,000 after purchasing an additional 149,124 shares during the last quarter. Finally, Cannell & Spears LLC grew its holdings in Regeneron Pharmaceuticals by 50.9% during the fourth quarter. Cannell & Spears LLC now owns 16,055 shares of the biopharmaceutical company’s stock valued at $11,436,000 after purchasing an additional 5,415 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 1.4 %

REGN opened at $625.60 on Thursday. The business’s fifty day simple moving average is $680.43 and its 200 day simple moving average is $786.93. Regeneron Pharmaceuticals, Inc. has a 52 week low of $605.56 and a 52 week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock has a market cap of $68.39 billion, a PE ratio of 16.34, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the company earned $11.86 EPS. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.56%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on REGN shares. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. BMO Capital Markets lowered their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 4th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. JPMorgan Chase & Co. lowered their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, Sanford C. Bernstein cut their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $966.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.